ClinicalTrials.Veeva

Menu
Clinical Trials Management, LLC | Southshore, Metairie, LA logo

Clinical Trials Management, LLC | Southshore, Metairie, LA

Research site

Site insights

Top conditions

Top treatments

Budesonide
Vonoprazan
Buprenorphine
Fluconazole
Difamilast
SCY-078
Apremilast
Lansoprazole
Ranolazine
Povorcitinib

Parent organization

This site is a part of Clinical Trials Management, LLC

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Active trials

9 of 66 total trials

A Phase 3 Study of Barzolvolimab in Participants with Chronic Spontaneous Urticaria (EMBARQ-CSU1)

The purpose of this study is to establish the efficacy, safety and tolerability of barzolvolimab in adult participants with Chronic Spontaneous Urtic...

Enrolling
Chronic Spontaneous Urticaria
Biological: barzolvolimab
Biological: Matching placebo

The objective of the Healing Phase of the study is to evaluate the safety and efficacy of up to 8 weeks of once daily oral administration of BLI5100...

Enrolling
Erosive Esophagitis
Drug: BLI5100
Drug: PPI Control

The purpose of this study is to evaluate the efficacy and safety of Povorcitinib (INCB054707) in participants with moderate to severe Hidradenitis Su...

Enrolling
Hidradenitis Suppurativa (HS)
Drug: Povorcitinib
Drug: Placebo
Locations recently updated

The purpose of this study is to evaluate long-term safety and efficacy of povorcitinib in participants with moderate to severe hidradenitis suppurati...

Enrolling
Hidradenitis Suppurativa (HS)
Drug: Povorcitinib

The purpose of this global Phase 2 study is to determine the efficacy, safety, and tolerability of 3 dose levels of OG-6219 in pre-menopausal women b...

Enrolling
Endometriosis
Drug: Placebo
Drug: OG-6219

The primary objectives of this study are to evaluate the safety and reactogenicity of mRNA-1403, and to demonstrate the efficacy of mRNA-1403 to prev...

Enrolling
Acute Gastroenteritis
Norovirus Acute Gastroenteritis
Biological: mRNA-1403
Biological: Placebo

The primary objective of this study is to evaluate the impact of LF111 and drospirenone (DRSP) 3.5 mg chewable tablets on bone mineral density (BMD)...

Enrolling
Change in Bone Mineral Density
Bone Loss
Drug: LF111 (drospirenone 4 mg oral tablet) or drospirenone (DRSP) 3.5 mg chewable tablet

This study is an open-label, uncontrolled study design to evaluate the long-term safety and tolerability of treatment with CC-93538. The study will e...

Enrolling
Eosinophilic Esophagitis
Drug: CC-93538

The aim of this 12-month randomized multi-regional double-blind parallel group allopurinol and placebo-controlled phase 3 study is to assess the effi...

Enrolling
Hyperuricemia
Tophi
Drug: Allopurinol
Drug: Tigulixostat

Trial sponsors

Janssen (J&J Innovative Medicine) logo
Shire logo
B
Incyte logo
Ironwood Pharmaceuticals logo
Phathom Pharmaceuticals logo
Acrotech Biopharma logo
Amgen logo
Bausch Health logo
C

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems